In the Original Investigation titled “Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial,” published in the January 5, 2021, issue of JAMA, the labels for some of the y-axes and panels were incorrect. Figure 2 parts A, C, and D should have included disease recurrence or death (instead of just mortality) in the labels for the panels and y-axes. This article has been corrected online.
